BioSig Confirms NASDAQ Listing for Common Stock
Ticker: STEX · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, exchange-listing
TL;DR
**BioSig's stock is still trading on NASDAQ, no changes.**
AI Summary
BioSig Technologies, Inc. filed an 8-K on January 30, 2024, to disclose that its Common Stock, with a par value of $0.001 per share, continues to be registered on The NASDAQ Capital Market under the trading symbol BSGM. This filing is a routine disclosure, confirming the company's ongoing compliance with exchange listing requirements. For investors, this means BioSig's shares remain publicly tradable on a major exchange, maintaining liquidity and visibility.
Why It Matters
This filing confirms BioSig's continued listing on NASDAQ, which is crucial for maintaining investor confidence, liquidity, and access to capital markets.
Risk Assessment
Risk Level: low — This is a routine informational filing with no new material events that would significantly alter the company's risk profile.
Analyst Insight
This filing is purely informational, confirming existing listing status. Investors should continue to monitor BioSig for more substantive operational or financial news rather than reacting to this routine disclosure.
Key Numbers
- $0.001 — Par Value per Share (The stated par value of BioSig Technologies, Inc.'s Common Stock.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — the registrant filing the 8-K
- The NASDAQ Capital Market (company) — the exchange where BioSig's common stock is registered
- BSGM (company) — the trading symbol for BioSig's common stock
- $0.001 (dollar_amount) — the par value per share of BioSig's common stock
- January 30, 2024 (date) — the date of the earliest event reported in the 8-K
FAQ
What is the purpose of this 8-K filing by BioSig Technologies, Inc.?
This 8-K filing by BioSig Technologies, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically disclosing information under Regulation FD and Financial Statements and Exhibits. It primarily confirms the continued registration of its Common Stock on The NASDAQ Capital Market.
On which exchange is BioSig Technologies, Inc.'s Common Stock registered?
BioSig Technologies, Inc.'s Common Stock, with trading symbol BSGM, is registered on The NASDAQ Capital Market, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the trading symbol for BioSig Technologies, Inc.'s Common Stock?
The trading symbol for BioSig Technologies, Inc.'s Common Stock is BSGM, as indicated in the 'Title of each class' table within the filing.
What is the par value per share of BioSig Technologies, Inc.'s Common Stock?
The par value per share of BioSig Technologies, Inc.'s Common Stock is $0.001, as specified in the filing under 'Common Stock, par value $0.001 per share'.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 30, 2024, as stated under 'Date of Report (Date of earliest event reported): January 30, 2024'.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-30 08:52:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-004245.txt ( ) — 244KB
- bsgm-20240130.xsd (EX-101.SCH) — 3KB
- bsgm-20240130_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240130_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: January 30, 2024 By: /s/ Kenneth L. Londoner Name: Kenneth L. Londoner Title: Executive Chairman